Asarina Pharma AB (publ)
F:APS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Asarina Pharma AB (publ)
F:APS
|
SE |
|
SRG Global Ltd
OTC:SRGGF
|
AU |
|
D
|
Donkeyrepublic Holding A/S
CSE:DONKEY
|
DK |
|
Y
|
Yi Jinn Industrial Co Ltd
TWSE:1457
|
TW |
|
Luxbright AB
F:LUR
|
SE |
|
G
|
GPS Alliance Holdings Ltd
ASX:GPS
|
SG |
|
H
|
Helios Techno Holding Co Ltd
TSE:6927
|
JP |
|
P
|
Powerlong Real Estate Holdings Ltd
XMUN:PW5
|
CN |
Asarina Pharma AB (publ)
Asarina Pharma AB is a Swedish biotech company, which is engaged in developing Sepranolone for allopregnanolonerelated stress, menstrual and neurological disorders. The company is headquartered in Solna, Stockholm. The company went IPO on 2018-09-24. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The firm conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.
Asarina Pharma AB is a Swedish biotech company, which is engaged in developing Sepranolone for allopregnanolonerelated stress, menstrual and neurological disorders. The company is headquartered in Solna, Stockholm. The company went IPO on 2018-09-24. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The firm conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.
